INCB059872
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed Ewing Sarcoma
Conditions
Relapsed Ewing Sarcoma
Trial Timeline
Jun 27, 2018 → Jun 25, 2020
NCT ID
NCT03514407About INCB059872
INCB059872 is a phase 1 stage product being developed by Incyte for Relapsed Ewing Sarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT03514407. Target conditions include Relapsed Ewing Sarcoma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed Ewing Sarcoma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03514407 | Phase 1 | Terminated |
| NCT03132324 | Phase 1 | Terminated |
Competing Products
20 competing products in Relapsed Ewing Sarcoma